

Final Report for the Clinical and Translational Science Pilot Grant Program

In general, the Final Report should follow the guidelines put forth in PHS 2590. The report should be a brief presentation of the accomplishments on the research project during the award, in language understandable to a biomedical scientist who may not be a specialist in the project's research field. The style used in *Science* articles would be appropriate. Abbreviations and language that may not be known to the broader scientific community should be avoided unless clearly defined.

The entire Final Report, exclusive of the list of publications and project-generated resources should not exceed two pages. The report should follow the outline shown below. Tables and figures that summarize key accomplishments are not counted in the two-page limit.

A. Specific Aims

.

B. Studies and Results

Describe the studies directed toward specific aims during the funding period and the positive and negative results obtained. If applicable, address any changes to the innovative potential of the project. If technical problems were encountered in carrying out this project, describe how your approach was modified.

C. Significance

Emphasize the significance of the findings to the scientific field and/or

- their potential for translation to useful products or processes
- advancement of an idea to a more developed technology
- disclosure of inventions or other discoveries to the office of Technology Transfer
- a clear statement of the success of the project in providing “proof-of-concept.”

D. Publications

Report publications resulting directly from this grant including manuscripts submitted or accepted for publication. Do NOT submit for publication without proper disclosure of possible inventions or other discoveries to the office of Technology Transfer. If there is any question about this, contact: <http://louisville.edu/thinker>

E. Project-Generated Resources

Report if the research supported by this grant resulted in: (1) a grant application, (2) a grant award, (3) data, research materials (such as cell lines, DNA probes, animal models), protocols, software, or other information available to be shared with other investigators, (4) Disclosures of Intellectual Property to the office of Technology Transfer.